---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117150"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:00:20.435895+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VYNE Q3 net loss $9.5M; VYN201 Phase 1a/b enrollment imminent; FMX114 strategy under review

## Summary
- Q3 2022 net loss $9.5M vs $21.3M; operating loss $9.3M vs $14.3M year-over-year.
- IND cleared for VYN201; first patient expected in Phase 1a/b vitiligo trial Nov. 2022 with topline data H1 2023.
- FMX114 Phase 2a missed primary endpoint at week 4 but statistically superior at weeks 1-3; evaluating strategy for moderate-to-severe AD.
- VYN202 oral BETi program progressing with Tay Therapeutics toward lead candidate selection.
- Corporate presentation posted; cash position not separately disclosed in released results.

## SEC filing metadata
- accession: 0001104659-22-117150
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/0001104659-22-117150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/tm2230087d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117150
- JSON: https://secwatch.observer/filing/0001104659-22-117150.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117150.txt

## Key facts
- Earnings Releases
  VYNE Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 ).
  - Period: three and nine months ended September 30, 2022
  - Net income: Net loss (GAAP) $ (9,459 ) $ (21,285 ) $ (13,265 ) $ (61,759 )
  - Result: reported results
  source text: VYNE Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465922117150/0001104659-22-117150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.